Silence Therapeutics

music heart
Biotech

Silence slows zerlasiran, as Hansoh leaves $1.3B biobucks collab

“We will only initiate the phase 3 cardiovascular outcomes study once a partner is secured,” Silence CEO Craig Tooman said.
James Waldron Feb 27, 2025 8:51am
blood test vials

Silence breaks down phase 1 data on blood disorder prospect

Jun 27, 2024 9:40am
megaphone yell showcase show off scream trumpet

Silence loses Mallinckrodt collab, wins in cardiovascular ph. 2

Mar 13, 2024 8:54am
arrow back backwards u-turn turn around reverse

Silence takes back 2 complement programs from Mallinckrodt

Mar 28, 2023 10:42am
cardiovascular heart pool

Amgen will take heart drug into phase 3 to challenge Novartis

Nov 7, 2022 11:40am
blood cancer

FDA grants Silence's drug fast-track tag for a blood cancer

Sep 8, 2022 9:10am